Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nipocalimab plus certolizumab in active rheumatoid arthritis
ISRCTN16927703Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2024
- Modality
- Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised trial in rheumatoid arthritis (RA) comparing Certolizumab + Placebo with Certolizumab + Nipocalimab (2 arms). Primary endpoint: Change in Disease Activity Score 28 using C-reactive Protein. Started Feb 2024; status: completed.
02
Drugs
nipocalimabcertolizumab pegol
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on ISRCTN16927703.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN16927703.